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PrognosisAbstract Lung cancer is the cancer killer among men and women worldwide. Attempts have been
undertaken to identify potential biomarkers for lung cancer; some of which have a direct impact on
tumor behavior. The association between MMPs and SDF-1 was previously studied in other organs
yet the current study is conducted to evaluate their immunohistochemical expression in non-small
lung cancer (NSCLC) aiming to discover their association with different clinicopathological prog-
nostic parameters.
Materials and methods: Bronchoscopy and/or C-T guided biopsy from 72 specimens of NSCLC
(27 adenocarcinomas, 23 squamous cell carcinomas, and 12 large cell carcinomas) were immunohis-
tochemically stained with MMPs and SDF-1.
Results: Cytoplasmic and stromal expression of MMP-2 was seen in 39 (54.2%) patients.
Nuclear SDF-1 staining was observed in 36 cases (50%). High expression of MMP-2 was correlated
with tumor size (P= 0.002), lymph node (P= 0.001) and distant metastasis (P= 0.026). Nuclear
SDF-1 expression was correlated with the tumor size (P= 0.001) and increased risk of metastasis
(P= 0.001). A strong agreement between both markers was detected. Combined expression of
MMP-2 and SDF-1 was significantly correlated with high tumor stage. MMP2 and nuclear
SDF-1 were significantly independent factors in predicting high tumor stage (III and IV).
Conclusion: SDF-1a directed invasion of NSCLC is mediated by crosstalk with MMP-2. The
identification of SDF-1a from NSCLC tissues as a potential stimulatory factor of MMP-2 during
cancer cell invasion may be involved in aggressiveness of NSCLC. Hence, identification of SDF-1a/
MMP-2 interaction may implicate therapeutic approaches for metastasis from lung cancer.
 2016 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Lung cancer, the cancer killer among men and women world-
wide, is considered to be a deadly illness because of low
(15%) 5 years – survival rate. This low survival rate is mainly
518 N.M. Osman, W.M. Osmanbecause most of subjects present with advanced stages at the
time of diagnosis. Advances in molecular biology have
improved the systematic efforts to identify molecular markers
for lung cancer with valuable predictive and prognostic signif-
icance [1].
Cancer prognostic markers are patient or tumor character-
istics that predict outcome independent of the treatment [2].
The goal of identifying prognostic markers is to define patient
subpopulations with significantly different anticipated out-
comes and who might benefit from different therapies [3].
Therefore, it is of great significance to make better under-
standing of the molecular biology of NSCLC invasion and
metastasis, and to identify novel molecular markers for the
improvement of clinical management of patients with NSCLC.
Mounting evidences supports the view that tumor microenvi-
ronment plays a critical role in tumorigenesis [4,5]. Although
there is a wide range of biological functions of tumor microen-
vironment in cancer, an important characteristic is the remod-
eling and stiffening of the extracellular matrix (ECM) [6,7].
Recent experimental studies have revealed that degradation
of the extracellular matrix (ECM) by matrix metallopro-
teinases (MMPs) is a critical process in progression of malig-
nant tumors, including NSCLC. This is because degradation
of the ECM is required in tumor invasion and metastases
[8–11]. Among many MMPs that have been identified,
MMP-2 (Gelatinase-A) and MMP-9 (Gelatinase-B) are
thought to be key enzymes as they degrade type IV collagen,
the main component of ECM [10,11]. Clinical studies on
MMP-2 in malignant tumors, including NSCLC, have been
conducted [12–15], but their clinical significance remains
controversial.
From the earliest work addressing the role of MMPs and
cancer, there has been a clear connection between certain
members of the MMP group and local cancer cell invasion
[16], but the association with metastatic disease has been less
clear. In addition to the ECM, MMPs have additional target
proteins which include other proteinases, proteinase inhibitors,
clotting factors, chemokines and chemotactic factors, growth
factors, a variety of cell surface receptors, and cell matrix
adhesion molecules [17].
Stromal cell–derived factor-1 (SDF-1), also called chemo-
kine (CXC) ligand 12 (CXCL12), is a chemotactic factor for
T cells, monocytes, hematopoietic progenitor cells, dendritic
cells, endothelial cells, and tumor cells [18–20]. One receptor
for this chemokine is CXCR4, which was previously called
fusin [21]. In addition to its chemotactic functions, SDF-1
has also been shown to regulate tumor cell proliferation,
motility, metastasis, and survival through its binding and sub-
sequent activation of CXCR4 [22–24]. In 2001, Muller et al.
[25] showed that the SDF-1/CXCR4 pathway mediates human
breast cancer metastasis. Several studies followed, providing
evidence that blocking of CXCR4 signaling in vivo using a
specific antibody [25], selective synthetic polypeptide [26], or
small interfering RNA [27] resulted in significant inhibition
of breast cancer metastasis to regional lymph nodes and the
lung. Similar results have also been reported for colonic adeno-
carcinoma and non-small cell lung cancer [28].
The association between MMPs and SDF-1 was previously
studied in other organs yet the current study is conducted to
evaluate the immunohistochemical expression of MMP-2 and
SDF-1 in NSCLC; aiming to discover their association with
different clinicopathological prognostic parameters.Materials and methods
Patients and tissues
This study included an overall 72 specimens of non-small lung
cancer (NSCLC) patients. Patients included were presented for
bronchoscopy and/or C-T guided biopsy at the chest depart-
ment, Ain Shams university hospital. The flexible bron-
choscopy (Pentax EB-1830T3 videobrochoschope, Asahi
Optical Co., Tokyo, Japan) was performed to all patients
according to the national and international standards of prac-
tice [29,30]. The diagnosis was based on the established pathol-
ogy in all patients. Staging included full history, physical
examination, blood tests and C-T scan (with contrast) of the
chest, pelvi- abdominal ultrasound and/or C-T. Bone scintigra-
phy and brain CT scan were performed only in case of symp-
toms. None of the patients received radiotherapy or adjuvant
chemotherapy. Formalin- fixed, Paraffin embedded tissue sam-
ples of 27 adenocarcinomas, 23 squamous cell carcinomas, and
12 cases of large cell carcinomas were included in the current
study. Collection of relevant clinical data and approval of
the Ethical Committee of Ain Shams University Hospitals
were fulfilled before proceeding in this study. The pathologist
independently examined the tumor specimens blinded from the
patients’ data to confirm the tumor type according to WHO
classification [31], tumor stage was revised as well according
to the TNM staging system [32].
Immunohistochemistry: All 72 specimens of non-small lung
cancer (NSLC) tissue samples were immunohistochemically
stained. Paraffin blocks were deparaffinized in xylene and
rehydrated through absolute alcohol. Antigen retrieval in
citrate buffer (pH9 Lab vision cat#AP9003) after treatment
in a microwave at 8 for 5–6 min, then at 3 for 10 min; After
cooling for 20 min, peroxidase and protein block was done.
Next, incubation overnight with the primary antibodies at
room temperature using MMP2 (purified pre diluted, 7 ml,
rabbit polyclonal MMP-2, cat. No. E18011, Spring Bioscience,
California, USA) and SFD-1 (purified pre diluted, 7 ml, rabbit
polyclonal, cat. No. E12541, Spring Bioscience, California,
USA), then rinsing in PBS (pH7.6). This was followed by the
secondary biotin conjugated antibody for 1 h and finally
another hour for the peroxidase conjugated streptavidin.
Diaminobenzidine tetrachloride (DAB) was added for
25 min. Then; counterstaining in Harris Hematoxylin,
followed by dehydration, clearing and mounting was done.
Positive control for MMp-2 antibody was ovarian carcinoma,
while that for SDF-1 was human tonsil. Negative controls
were done by replacement of the primary antibody with a
non-immune antibody.
MMP-2 staining: Five different fields (400) were
randomly examined. The immunoreactivity score method to
evaluate the immunostaining results has been previously
described [33]. Stain intensity is as follows: no staining (score
0), weak staining (score 1), moderate staining (score 2), or
strong staining (score 3). Staining area is as follows: less than
10% (score 1), 11–50% (score 2), 51–80% (score 3), 81–100%
(score 4). Points for staining intensity and percentage of posi-
tive tumor cells were added and the overall score was grouped
into four categories: negative (610% of tumor cells stained
positive, regard-less of intensity), weak expression (score 3),
moderate expression (score 4–5), and strong expression (score
SDF-1 and MMP2 cross talk in cancer cells 5196–7). Moderate and strong expression was rated as positive,
while weak expression was rated as negative for analysis.
SDF-1: The intensity of staining (1–3) and percentage of
positive cells (1 =<10%, 2 = 10–50%, 3 =>50%) were
taken into account to define a composite score. Positive
nuclear staining was defined as a nuclear score of 6 or 9 [i.e.
any slide with >50% of the cells expressing nuclear staining
(3) with intermediate or strong intensity (2 or 3)]. Cells were
counted in at least three fields (at 400) in the tumor areas
[34].
Evaluation and statistical analysis
Continuous variables are expressed as mean and Standard
Deviation. Categorical variables are expressed as frequencies
and percents. Student t test was used to assess the statistical
significance of the difference between two study group mean.
Chi square and Fisher’s exact test was used to examine the
relationship between Categorical variables. Logistic regression
was used for prediction of high stage tumor based on the pres-
ence of tumor markers. A significance level of P< 0.05 was
used in all tests. All statistical procedures were carried out
using SPSS version 15 for Windows (SPSS Inc, Chicago, IL,
USA).Results
The clinical-pathological data
Seventy-two specimens of NSCLC patients were included in
the present study. The mean age was 52.67 years
(±7.99 SD), 10 patients (14%) were female. 10 patients
(14%) were nonsmokers, and 11 were x-smokers (15.3%).
The mean tumor size was 5.80 cm (3.30 ± SD). The adenocar-
cinoma histologic subtype was present in 27 cases (37.5%),
squamous cell carcinoma in 33 cases (45.8%) and 12 cases
of large cell carcinoma type (16.7%). The commonest histo-
logic grade was poorly differentiated (33/72; 55%) and the
commonest tumor was classified as T1 in (24) patients
(33%). Lymph node metastatic involvement was detected
in (58) patients (80.6%). Twelve patients (16.7%) devel-
oped an evidence of metastatic disease at the time of diagnosis.
Hence, AJCC stages at time of biopsy were as follows: 14
(19.5%) stage I, 23 (32%) stage II, 23 (31.9%) stage III and
12 (16.7) stage IV.
MMP-2 expression in NSCLC: pattern of expression
Expression of MMP-2 was seen mainly in the cytoplasm of
tumor cells, and strong MMP-2 expression in tumor cells were
seen in 39 (54.2%) patients. Staining in the surrounding
stroma was localized in peri-tumoral fibroblasts and inflamma-
tory cells. Interestingly, the tumor stroma showed the same
score as that of the tumor cells. Strong MMP-2 expression
was more frequent in adenocarcinoma patients (19 of 39,
48.7%) than in squamous cell carcinoma patients (13 of 39,
33.3%) but it didn’t reach a significant difference P_0.054).
A high expression of MMP-2 was correlated with lymph node
and distant metastasis (P= 0.001, P= 0.026 respectively).
This was also noticed in the subgroup of squamous cell carci-nomas (P= 0.001). Also, association was found between the
expression of MMP-2 in tumor cells and tumor size
(P= 0.002), But no association was found between the expres-
sion of MMP-2 in tumor cells and tumor differentiation
(P= 0.556) (Table 1). There was no significant correlation
between tumoral MMP-2 status and any other patient charac-
teristic (data not tabulated).
Representative images of MMP-2 immunostaining in dif-
ferent types of NSCLC tissues are shown in Figs. 1–3.
SDF-1 expression in NSCLC: pattern of expression
SDF-1 was detected in the nucleus and/or in the cytoplasm of
tumor cells. Nuclear staining was observed in 36 cases (50%).
Interestingly, tumor cells exhibited also cytoplasmic staining
for SDF-1 in 28 cases (38.9%). The intensity of nuclear stain-
ing was always intermediate or strong whenever present. A
high expression of SDF_1 in tumor cells was correlated with
an increased risk for metastasis (P= 0.001), which was also
noticed in the subgroup of squamous cell carcinomas
(P= 0.004). Also, a positive correlation was found with the
tumor size (P= 0.001). In the patients with squamous cell
carcinoma, SDF-1expression was correlated with the presence
of metastasis (P= 0.001) (Table 2). There was no significant
correlation between SDF-1 expression and tumor differentia-
tion .age, gender, or smoking (data not tabulated). Represen-
tative images of SDF-1 immunostaining in different types of
NSCLC tissues are shown in Figs. 4–6.
MMP-2 Status and SDF-1 Biomarker
A strong agreement between nuclear SDF_1 and MMP2 was
detected (KAPPA= 0.750), as 84.6% of positive MMP2 were
positive nuclear SDF_1, and 90.9% of negative MMP2 was
negative nuclear SDF_1 (Table 3).
Moreover, combined expression of both SDF-1 and MMP-
2 expression is significantly correlated with high tumor stage.
Logistic regression showed that MMP2, and nuclear SDF-1
were significant independent factors predicting cases with high
tumor stage (III and IV), as positive MMP2, positive nuclear
SDF-1 are associated with 21 and 24 higher risk of Higher
tumor stage respectively. Also Nagelkerke R Square (0.788)
was highest on using both markers for prediction of higher
tumor stage (Table 4).
Discussion
Many attempts have been undertaken by scientists worldwide
to identify potential biomarkers for lung cancer; the world No.
1 among cancer killers. Unfortunately, the acceptance of these
markers as part of any of the diagnostic or prognostic proce-
dures in lung cancer patients has been limited [1].
The present era belongs to personalized chemotherapy, and
treatment choices based on molecular profiling are being stud-
ied intensely worldwide. These molecules are numerous, some
of which have conclusively and consistently been shown to
directly impact tumor behavior [35]. In the current study we
aimed to focus immunohistochemically on two promising
molecules; MMP-2 and SDF-1in NSCLC.
Cancer invasion and metastasis are multi-factor, multi-step
dynamic processes that involve the degradation of extracellular
Table 1 Relation between tumor characteristics and MMP2 expression among all tumor cases.
Tumor characteristics MMP2 P Sig
Positive Negative
No. % No. %
T stage T1 2 5.1 22 66.7 0.001* HS
T2 14 35.9 9 27.3
T3 12 30.8 1 3.0
T4 11 28.2 1 3.0
LN metastasis N0 2 5.1 12 36.4 0.001* HS
N1 7 17.9 19 57.6
N2 13 33.3 1 3.0
N3 17 43.6 1 3.0
N4 0 0.0 0 0.0
Distant Metastasis M0 29 74.4 31 93.9 0.026* S
M1 10 25.6 2 6.1
Stage I 2 5.1 12 36.4 0.001* HS
II 4 10.3 19 57.6
III 23 59.0 0 0.0
IV 10 25.6 2 6.1
Stage Stage I/II 6 15.4 31 93.9 0.001* HS
Stage III/IV 33 84.6 2 6.1
Mean ±SD Mean ±SD
Tumor size 5.99 2.03 3.42 1.82 0.002 HS
 Student t test.
* Chi square test.
Figure 1 (A) and (B) Large cell carcinoma with positive cytoplasmic MMP-2 immunostaining of the tumor cells as well as the
intervening tumor strom. (A) and (B) IHC  200, insets showed higher magnification of tumor cells. (IHC  400).
520 N.M. Osman, W.M. Osmanmatrix and basement membrane. MMPs are an important
family of proteolytic enzymes that significantly contribute to
tumor microenvironment remodeling and associate with
tumorigenesis and metastasis [36].
In the current study, MMP-2 was detected in the cytoplasm
of tumor cells as well as in the surrounding tumor stroma. This
is consistent to previous studies [12,37,38]. The importance of
tumor–stroma interactions regulating cancer development has
been fully pointed out in some previous studies [39,40].
Additionally, Matrix metalloproteinases (MMPs) are pro-
teolytic enzymes which are proved to enhance tumor invasion
and metastasis [39,41]. This was also proved in this study as
high expression of MMP-2 was correlated with lymph nodeand distant metastasis. Passlick et al. [12]; Kumaki et al. [13]
and Ishikawa et al. [38], stated that in lung carcinomas either
increased stromal or cancer cell associated with MMP-2
expression has been found to correlate with poor outcome.
Furthermore, once a lesion is initiated, cancer associated
fibroblasts ‘‘CAFs” have been shown to assist in proliferation
and progression of cancer through the production of growth
factors and chemotactic factors, angiogenesis factors, and
MMPs, allowing invasion and spread of cancer cells i.e. cre-
ation of the metastatic niche [38].
Besides, Ma et al. [42] conducted a comparative analysis of
gene expression changes and found that the genetic changes of
the tumor-associated stroma were similar to those of the tumor
Figure 2 (A) and (B) Moderately and poorly differentiated adenocarcinoma with positive cytoplasmic of MMP-2 immunostaining of the
tumor cells as well as the intervening tumor strom. (A) and (B) IHC  400).
Figure 3 (A) and (B) Moderately and poorly differentiated squamous cell carcinoma with positive cytoplasmic of MMP-2
immunostaining of the tumor cells as well as the intervening tumor strom. (A) and (B) IHC  200).
SDF-1 and MMP2 cross talk in cancer cells 521epithelium. In particular, they found that tumor stroma that
had reached the invasive stage expressed an increased level
of MMPs, such as MMP-2. Accordingly, these findings sup-
port the theory that the tumor mass and its microenvironment
have reciprocal relationships with both undergoing genetic
expression alterations in cancer [43–45].
Conversely, in other studies the relationship of MMP-2
expression with other clinicopathological parameters predict-
ing tumor aggressiveness has remained controversial
[12,46,47]. In the current study, however; the MMP-2 expres-
sion was also found to be correlated with tumor size. This
may be explained by the abnormal interplay consisting of
cell–cell contact and active molecular crosstalk which further
drives the cancer stroma phenotype, leading to direct stimula-
tion of tumor cell growth. This unique interplay between the
various aspects of the tumor cells and the microenvironment
has been the recent target of molecular strategies for tumor
treatment [48].
The function of MMPs is adjusted by the action of both dif-
ferent inducers and inhibitors, which regulate their tissue speci-
fic expression [40,49]. Chemokines structurally related small
(8–14 kD) polypeptide signaling molecules, can bind to and
activate a family of seven trans-membrane receptors [50,51].
Chemokines are expressed by many tumor types and can pro-
mote mitosis, modulate apoptosis, survival and angiogenesis
[28,52]. To date, 19 chemokine receptors have been identified,
one of these is SDF1 (also called CXCR12), is expressed in
lung, bone and liver [34].Stromal cell-derived factor (SDF-1) is a member of the
superfamily of chemo-attractant chemokines [53]. In the cur-
rent study, SDF-1 was overexpressed in 50% of NSCLC cases.
Overexpression of SDF-1 was associated with poor prognostic
parameters of NSCLC. The high expression of SDF_1 in
tumor cells was correlated with an increased risk for LN
metastasis, tumor size and distant metastasis. Therefore, tar-
geting SDF-1 pathway may offer new potential therapeutic
strategies for NSCLCs. This is in concordance with many stud-
ies that showed SDF-1 [53–55] expression was reported in a
variety of tumor cell lines and human cancer samples, includ-
ing malignant tumors from breast, brain, lung, kidney, esoph-
agus, and skin [53,55–59]. High levels of SDF-1 expression
correlate with metastasis and recurrence in non-small cell lung
cancer [60].
Additionally, a previous study – by Mundy (2002) [61],
revealed that SDF-1 secreted from bone cells (including osteo-
blasts and stromal cells) plays a key role in lung cancer cell
metastasizing to bone.
SDF-1a mediated invasion may involve the activation and
secretion of MMP-2 [62,63]. This is in concordance to the cur-
rent study which declared the direct relationship and strong
agreement between both molecules in NSCLC cases. Thus,
NSCLC cells have been shown to migrate and invade through
ECM components in response to SDF-1a- actions, which is
associated with enhanced expressions of MMP-2. This is also
in agreement with Hung et al. (2010) [64] and Sze etal.
(2011) [65]. However; McQuibban et al. [66], stated that
Table 2 Relation between tumor characteristics and nuclear SDF_1 expression in all tumor cases.
Tumor characteristics SDF-1 nuclear SDF-1 cytoplasmic P Sig
Positive Negative Positive Negative
Mean ±SD Mean ±SD Mean ±SD Mean ±SD
T stage T1 0 0.0 24 66.7 20 71.4 4 9.1 0.001* HS
T2 13 36.1 10 27.8 6 21.4 17 38.6
T3 11 30.6 2 5.6 2 7.1 11 25.0
T4 12 33.3 0 0.0 0 0.0 12 27.3
LN metast. N0 0 0.0 14 38.9 10 35.7 4 9.1 0.001* HS
N1 5 13.9 21 58.3 17 60.7 9 20.5
N2 14 38.9 0 0.0 0 0.0 14 31.8
N3 17 47.2 1 2.8 1 3.6 17 38.6
Distant Metast M0 24 66.7 36 100.0 28 100% 32 72.7 0.002** HS
M1 12 33.3 0 0.0 0 0.0 12 27.3
Stage I 0 0.0 14 38.9 10 35.7 4 9.1 0.001* HS
II 4 11.1 19 52.8 15 53.6 8 18.2
III 20 55.6 3 8.3 3 10.7 20 45.5
IV 12 33.3 0 0.0 0 0.0 12 27.3
Stage Stage I/II 4 11.1 33 91.7 25 89.3 12 27.3 0.001* HS
Stage III/IV 32 88.9 3 8.3 3 10.7 32 72.7
Mean ±SD Mean ±SD Mean ±SD Mean ±SD
Tumor size 6.18 1.91 3.44 1.83 3.45 1.93 5.68 2.12 0.001 HS
* Chi square test.
** Fisher exact test.
 Student t test.
Figure 4 (A) and (B) Large cell carcinoma with positive nuclear SDF-1 a immunostaining of the tumor cells (A) IHC  200, (B)
IHC  400 respectively).
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-9 and -14 in vitro. Also, MMPs are proposed to display anti-
metastatic properties through CXCL12/SDF-1 cleavage [41].
But noticeably this is not true regarding tumors of the lung
and MMP-2 where the microenvironment consists of an amal-
gam of secreted soluble factors, non-cellular solid material,
and stromal cells that directly surround the tumor cells. Also
these secreted soluble factors from the tumor cells are stored
and released when required by the tumor cells [67,68].
Moreover, Logistic regression in the present study showed
that MMP2, and SDF-1 nuclear were significant independent
factors predicting cases with high tumor stage (3 and 4), aspositive MMP2, nuclear SDF-1 are associated with 21 and
24 higher risk of higher tumor stage respectively. These find-
ings suggest a promising role for the SDF-1a/MMP-2 axis in
the metastatic evolution of NSCLC, and its potential use as
prognostic markers and drug targets.
In conclusion, we present here a novel mechanism of SDF-
1a directed invasion of lung cancer cells by crosstalk with
MMP-2 protein. The identification of SDF-1a from NSCLC
tissues as a potential stimulatory factor of MMP-2 during
human cancer cell invasion may help understand the mecha-
nisms involved in the aggressive potential of lung cancer cells.
In addition, the identification of SDF-1a/MMP-2 interaction
Figure 5 (A) and (B) Well and moderately differentiated adenocarcinoma with positive nuclear/cytoplasmic SDF-1 immunostaining of
the tumor cells (A) and (B) IHC  400).
Figure 6 (A) and (B) Well and moderately differentiated squamous cell carcinoma with positive nuclear SDF-1 immunostaining of the
tumor cells respectively (A) and (B) IHC  400).
Table 3 Agreement between MMP2 and SDF-1 nuclear.
MMP2 Kappa Sig
Positive Negative
N % N %
Nuclear SDF_1 Positive 33 84.6 3 9.1 0.750 0.001
Negative 6 15.4 30 90.9
Table 4 Logistic regression to study the effect of MMP and
nuclear SDF-1 immunoexpression on tumor stage.
OR P Sig 95% C.I. for
OR
Nagelkerke
R square
Lower Upper
MMP2
(1)
21.064 0.002 HS 3.062 144.901 0.788
Nuclear
SDF_1
24.229 0.0001 HS 4.061 144.565
SDF-1 and MMP2 cross talk in cancer cells 523as an important factor in the invasiveness of human lung can-
cer cells may implicate potential therapeutic approaches for
metastasis from lung cancer.References
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